Fox Run Management L.L.C. Makes New $1.30 Million Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Fox Run Management L.L.C. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 35,900 shares of the specialty pharmaceutical company's stock, valued at approximately $1,298,000. Fox Run Management L.L.C. owned about 0.07% of Supernus Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Exchange Traded Concepts LLC boosted its position in shares of Supernus Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock worth $800,000 after buying an additional 560 shares during the period. HighTower Advisors LLC raised its holdings in Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after purchasing an additional 624 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Supernus Pharmaceuticals by 0.5% during the 4th quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company's stock valued at $6,236,000 after purchasing an additional 800 shares in the last quarter. Swiss National Bank boosted its holdings in Supernus Pharmaceuticals by 0.7% during the fourth quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company's stock worth $3,920,000 after buying an additional 800 shares in the last quarter. Finally, Quartz Partners LLC boosted its stake in shares of Supernus Pharmaceuticals by 3.0% during the 4th quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company's stock worth $1,031,000 after acquiring an additional 820 shares in the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SUPN. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com cut Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday.

Supernus Pharmaceuticals Trading Down 2.2 %

NASDAQ SUPN traded down $0.72 on Wednesday, reaching $32.33. The stock had a trading volume of 277,635 shares, compared to its average volume of 466,455. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 30.22 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The business has a 50 day moving average price of $35.37 and a 200 day moving average price of $35.03.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.